HAE

NEUTRALTechnical

Haemonetics Corporation

2026-09-23

Price

$106.82

-1.57%

This is the 2026-09-23 snapshot — the signals and analysis for HAE as of this single trading day.

View full HAE research hub →

Score8.0Priority

Signals4/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 7

Volume1.1xvs 20d avg

Analysis

Haemonetics (HAE) is currently digesting a massive 48% 90-day run-up fueled by a renewed CSL Plasma supply deal and an enterprise-wide margin expansion narrative. Technical signals like STEADY_CLIMB and PERFECT_STACK confirm deep institutional accumulation, suggesting the recent 1.5% pullback is merely routine profit-taking near analyst fair-value targets rather than trend exhaustion. Supported by a robust RISK_ON macro regime and strong PMI data that is overpowering rate jitters, HAE's market leadership profile makes this consolidation a highly constructive setup for continuation.

Fired Signals

STEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKBARGAIN HUNTERDISTRIBUTION

Key Takeaways

Actionable Thesis: Accumulate shares during this minor consolidation phase, as the structural drivers of margin expansion and the CSL Plasma deal remain firmly intact.
Key Risk: A higher debt load and concentrated exposure to key product lines (NexSys, TEG) leave the stock vulnerable to execution stumbles or margin compression.
What to Watch: Price action around the $101.06 line-in-the-sand; holding this 20-day low confirms the bullish momentum is still absorbing supply.

← Back to 2026-09-23 View Full HAE History →Yahoo Finance &nearr;